Items where authors include "Mariette, X"

Article

Aletaha, D, Kerschbaumer, A, Kastrati, K et al. (41 more authors) (2022) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases. ISSN 0003-4967

Alunno, A, Najm, A, Machado, PM et al. (21 more authors) (2021) 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases. ISSN 0003-4967

Alunno, A, Najm, A, Mariette, X et al. (5 more authors) (2021) Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. RMD Open, 7 (3). e001899. ISSN 2056-5933

Alunno, A, Najm, A, Mariette, X et al. (5 more authors) (2021) Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Annals of the Rheumatic Diseases. ISSN 0003-4967

Najm, A, Alunno, A, Mariette, X et al. (6 more authors) (2021) Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open, 7 (1). e001549. ISSN 2056-5933

Alunno, A, Najm, A, Machado, PM et al. (21 more authors) (2021) EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases. ISSN 0003-4967

Smolen, JS, Landewé, RB, Bijlsma, JWJ et al. (44 more authors) (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases. ISSN 0003-4967

Tarn, JR, Howard-Tripp, N, Lendrem, DW et al. (48 more authors) (2019) Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. The Lancet Rheumatology, 1 (2). e85-e94. ISSN 2665-9913

Aringer, M, Costenbader, K, Daikh, D et al. (61 more authors) (2019) 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 71 (9). pp. 1400-1412. ISSN 2326-5191

Aringer, M, Costenbader, K, Daikh, D et al. (61 more authors) (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78 (9). pp. 1151-1159. ISSN 0003-4967

Weinblatt, ME, Bingham, CO, Burmester, G-R et al. (9 more authors) (2017) A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 69 (10). pp. 1937-1948. ISSN 2326-5191

Fisher, BA, Jonsson, R, Daniels, T et al. (18 more authors) (2017) Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 76 (7). pp. 1161-1168. ISSN 0003-4967

Smolen, JS, Landewé, R, Bijlsma, J et al. (46 more authors) (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76 (6). pp. 960-977. ISSN 0003-4967

Sellam, J, Rivière, E, Courties, A et al. (11 more authors) (2017) Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research and Therapy, 19. 11. ISSN 1478-6354

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases, 76 (1). pp. 96-104. ISSN 0003-4967

Sellam, J, Riviere, E, Courties, A et al. (11 more authors) (2016) Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research & Therapy, 18. 294. ISSN 1478-6354

Bykerk, VP, Emery, P, Weinblatt, ME et al. (7 more authors) (2016) PMS82 – Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. Value in Health. ISSN 1098-3015

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2016) Response to: ‘Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!’ by Boers. Annals of the Rheumatic Diseases, 75 (10). e69. ISSN 0003-4967

Dougados, M, Devauchelle-Pensec, V, Ferlet, JF et al. (15 more authors) (2013) The ability of synovitis to predict structural damage in rheumatoid arthritis: A comparative study between clinical examination and ultrasound. Annals of the Rheumatic Diseases, 72 (5). pp. 665-671. ISSN 0003-4967

Conference or Workshop Item

Alunno, A, Najm, A, Mariette, X et al. (5 more authors) (2021) OP0287 IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER. In: EULAR 2022 – Annual European Congress of Rheumatology, 02-05 Jun 2021, Copenhagen, Denmark.

Najm, A, Alunno, A, Mariette, X et al. (7 more authors) (2021) POS0052 Pathophysiology of Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Literature Review to Inform Eular Points to Consider. In: EULAR 2021 Annual European Congress of Rheumatology, 02-05 Jun 2021, Online.